Non-Hodgkin lymphoma (NHL) is the seventh most common
malignancy in the United States; its incidence has been increasing
by an annual average of 0.5% for the past decade. Aggressive NHL
(aNHL) has been defined by the National Cancer Institute as a type
of lymphoma that grows and spreads quickly and results in severe
symptoms.1 Standard treatment of aNHL usually includes cyclophosphamide,
doxorubicin, vincristine, and prednisone combined